Our Pricing

Mounjaro Dosage Timeline: What Happens Week by Week

Understanding the mounjaro dosage timeline week by week is essential for managing expectations and optimising your weight loss journey. Mounjaro (tirzepatide) follows a carefully structured dose escalation protocol, starting at 2.5mg and gradually increasing to a maintenance dose based on your individual response and tolerability. This week-by-week guide explains exactly what happens at each stage, from your first injection through to long-term maintenance.

Weeks 1-4: Starting Dose (2.5mg)

Every Mounjaro treatment begins with a 2.5mg weekly injection for the first four weeks. This initial dose serves as a tolerance-building phase rather than a therapeutic dose, allowing your body to adjust to tirzepatide's dual GIP/GLP-1 receptor activation [1]. During this period, the medication begins modulating appetite hormones and slowing gastric emptying, though significant weight loss is not typically expected yet.

Common experiences during weeks 1-4 include mild nausea (affecting approximately 20% of patients in clinical trials), reduced appetite, and occasional digestive changes [1]. These side effects are generally mild and diminish as your body adapts. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can help manage early gastrointestinal symptoms.

Your UK prescriber will confirm you're ready to progress to the next dose after completing four weeks at 2.5mg. This initial phase establishes the foundation for safe, effective dose escalation throughout your treatment journey.

Weeks 5-8: First Dose Increase (5mg)

After four weeks at the starting dose, you'll increase to 5mg weekly injections. This is where many patients begin noticing more pronounced appetite suppression and early weight loss. In the SURMOUNT-1 trial, patients at the 5mg dose achieved an average 15.0% body weight reduction over 72 weeks, demonstrating this dose's clinical efficacy for many individuals [1].

The transition to 5mg may temporarily intensify side effects you experienced during the first month, or introduce new ones. Approximately 25-30% of patients report mild to moderate nausea during this escalation phase, though symptoms typically resolve within 1-2 weeks as your body adjusts to the higher dose [2]. Fatigue and occasional constipation are also reported during this period.

Some patients find 5mg becomes their long-term maintenance dose if they achieve satisfactory weight loss and tolerate it well. Your prescriber will assess your progress at regular intervals to determine whether further dose escalation is appropriate or whether maintaining at 5mg meets your treatment goals.

Managing Side Effects During Dose Increases

Each dose escalation can trigger a temporary recurrence or intensification of gastrointestinal side effects. Eating slowly, choosing bland foods, and avoiding large meals helps minimise nausea and discomfort. If side effects become problematic, your UK prescriber may recommend staying at your current dose for an additional four weeks before attempting the next increase.

Weeks 9-12: Second Dose Increase (7.5mg)

The 7.5mg dose represents a mid-range therapeutic level where weight loss typically accelerates. Clinical trial data shows patients at this dose achieve substantial reductions in body weight whilst maintaining good tolerability profiles [1]. This phase often marks a turning point where appetite suppression becomes more consistent and eating behaviours change significantly.

By weeks 9-12, your body has adapted to tirzepatide's mechanisms, and side effects generally become less frequent or severe compared to earlier escalation phases. However, individual responses vary—some patients experience renewed nausea or digestive changes when moving to 7.5mg, whilst others transition smoothly with minimal symptoms.

Your prescriber will evaluate whether continuing to higher doses is clinically appropriate based on your weight loss progress, side effect profile, and overall health markers. For some patients, 7.5mg provides optimal balance between efficacy and tolerability, making it a suitable long-term maintenance dose.

Weeks 13-16: Third Dose Increase (10mg)

The 10mg dose is often considered the first true maintenance dose for many patients. At this level, tirzepatide's dual receptor activation produces significant metabolic effects, including improved insulin sensitivity, reduced hepatic glucose production, and sustained appetite regulation [2]. Patients typically report feeling satisfied with smaller portions and experiencing fewer food cravings.

Weight loss continues steadily at 10mg, with clinical trials demonstrating an average 19.5% body weight reduction over 72 weeks at this dose level [1]. This represents substantial clinical benefit for most individuals, particularly when combined with dietary modifications and increased physical activity.

Some patients remain at 10mg as their final maintenance dose, especially if they've achieved their target weight loss or prefer not to escalate further. Others continue to higher doses under prescriber guidance to maximise therapeutic benefit.

Plateau Periods and Dose Optimisation

Weight loss is rarely linear—plateaus lasting 2-4 weeks are normal and don't necessarily indicate treatment failure. Your prescriber may recommend maintaining your current dose through a plateau rather than immediately escalating, as weight loss often resumes without intervention. Patience during these phases is essential for long-term success.

Weeks 17-20: Fourth Dose Increase (12.5mg)

The 12.5mg dose is prescribed for patients who tolerate lower doses well but require additional support to reach their weight loss goals. This higher dose intensifies tirzepatide's effects on appetite-regulating hormones and glucose metabolism, producing enhanced clinical outcomes in suitable candidates [2].

By this stage of treatment, most patients have developed effective strategies for managing side effects and integrating Mounjaro into their daily routines. The transition to 12.5mg is often smoother than earlier escalations, as your body has adapted to tirzepatide's mechanisms over four months of treatment.

Your UK prescriber will monitor your progress closely at this dose, assessing both efficacy markers (weight loss, waist circumference, metabolic parameters) and safety indicators. Not all patients require escalation to 12.5mg—the decision depends on individual treatment response and clinical need.

Weeks 21+: Maximum Dose (15mg) and Long-Term Maintenance

The 15mg dose represents the maximum licensed dose of Mounjaro in the UK and produces the most substantial weight loss outcomes. In the SURMOUNT-1 trial, patients receiving 15mg tirzepatide achieved an average 22.5% body weight reduction over 72 weeks—the highest efficacy demonstrated in obesity pharmacotherapy to date [1]. This dose is reserved for patients who tolerate escalation well and require maximum therapeutic effect.

Long-term maintenance on Mounjaro requires ongoing prescriber oversight, typically through quarterly reviews assessing weight trends, side effects, and overall health status. Treatment duration varies by individual—some patients achieve their goals within 12-18 months, whilst others benefit from longer-term therapy to maintain weight loss and metabolic improvements.

At Cured Pharmacy, Mounjaro is available from £135.00 with transparent upfront pricing and free clinical consultations by UK-registered prescribers. All doses require assessment and prescription approval, ensuring your treatment plan is tailored to your specific needs and medical history.

When to Contact Your Prescriber

Contact your UK prescriber immediately if you experience severe abdominal pain, persistent vomiting, signs of pancreatitis, or any concerning symptoms during treatment. Regular check-ins ensure your dose escalation proceeds safely and adjustments can be made if needed. Never increase your dose without prescriber approval, as premature escalation increases side effect risk without improving outcomes.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including diet, exercise, and adherence to the prescribed dosing schedule.